Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by stockman6767on Nov 24, 2016 9:26am
186 Views
Post# 25507412

RE:RE:RE:Facts from the analist day and Prometic confirmed by Fred

RE:RE:RE:Facts from the analist day and Prometic confirmed by FredBepando, you wrote : "there now estimated 4000 to 6000 patients/year."  Do we know if these are NEW patients each year, or perhaps the number of total patients in any year which includes those from the previous year that still continue to survive? this of course would make a big difference whether as you suggest that in year 3 for example PLI might have near 15,000 patients vs. only 5,000 patients (in any year).
Bullboard Posts